These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 25882026)

  • 1. Comparative healthcare costs in patients with metastatic melanoma in the USA.
    Chang CL; Schabert VF; Munakata J; Donga P; Abhyankar S; Reyes CM; Yim YM
    Melanoma Res; 2015 Aug; 25(4):312-20. PubMed ID: 25882026
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Modelling Comparative Efficacy of Drugs with Different Survival Profiles: Ipilimumab, Vemurafenib and Dacarbazine in Advanced Melanoma.
    Lee D; Porter J; Hertel N; Hatswell AJ; Briggs A
    BioDrugs; 2016 Aug; 30(4):307-19. PubMed ID: 27177756
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post hoc economic analysis of temozolomide versus dacarbazine in the treatment of advanced metastatic melanoma.
    Hillner BE; Agarwala S; Middleton MR
    J Clin Oncol; 2000 Apr; 18(7):1474-80. PubMed ID: 10735895
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Patterns of use of systemic therapies among patients with metastatic melanoma: a retrospective claims database analysis in the United States.
    Ma Q; Chen YJ; Hines DM; Munakata J; Batty N; Barber BL; Zhao Z
    J Dermatolog Treat; 2017 Sep; 28(6):549-553. PubMed ID: 28100090
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Drug treatment for melanoma: progress, but who pays?
    Kefford RF
    Med J Aust; 2012 Aug; 197(4):198-9. PubMed ID: 22900855
    [No Abstract]   [Full Text] [Related]  

  • 6. Economic burden associated with adverse events in patients with metastatic melanoma.
    Arondekar B; Curkendall S; Monberg M; Mirakhur B; Oglesby AK; Lenhart GM; Meyer N
    J Manag Care Spec Pharm; 2015 Feb; 21(2):158-64. PubMed ID: 25615005
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost and economic burden of adverse events associated with metastatic melanoma treatments in five countries.
    Vouk K; Benter U; Amonkar MM; Marocco A; Stapelkamp C; Pfersch S; Benjamin L
    J Med Econ; 2016 Sep; 19(9):900-12. PubMed ID: 27123564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A Network Meta-Analysis of Short and Long-Term Efficacy of Targeted Therapy With Single or Double-Drug Regimens in the Treatment of Stage III/IV Malignant Melanoma Based on 16 Randomized Controlled Trials.
    Xie T; Huang CY; Kang X; Luo JS; Qin XM; Han F
    J Cell Biochem; 2018 Jan; 119(1):640-649. PubMed ID: 28628251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Survival of melanoma patients treated with novel drugs: retrospective analysis of real-world data.
    Polkowska M; Ekk-Cierniakowski P; Czepielewska E; Wysoczański W; Matusewicz W; Kozłowska-Wojciechowska M
    J Cancer Res Clin Oncol; 2017 Oct; 143(10):2087-2094. PubMed ID: 28608286
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Costs, resource utilization, and treatment patterns for patients with metastatic melanoma in a commercially insured setting.
    Toy EL; Vekeman F; Lewis MC; Oglesby AK; Duh MS
    Curr Med Res Opin; 2015 Aug; 31(8):1561-72. PubMed ID: 26086578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Healthcare costs associated with bevacizumab and cetuximab in second-line treatment of metastatic colorectal cancer.
    Yang H; Yu AP; Wu EQ; Yim YM; Yu E
    J Med Econ; 2011; 14(5):542-52. PubMed ID: 21728912
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The burden of metastatic melanoma: treatment patterns, healthcare use (utilization), and costs.
    Reyes C; DaCosta Byfield S; Linke R; Satram-Hoang S; Teitelbaum AH
    Melanoma Res; 2013 Apr; 23(2):159-66. PubMed ID: 23370422
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Direct costs associated with adverse events of systemic therapies for advanced melanoma: Systematic literature review.
    Copley-Merriman C; Stevinson K; Liu FX; Wang J; Mauskopf J; Zimovetz EA; Chmielowski B
    Medicine (Baltimore); 2018 Aug; 97(31):e11736. PubMed ID: 30075584
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The economic burden of common adverse events associated with metastatic colorectal cancer treatment in the United States.
    Latremouille-Viau D; Chang J; Guerin A; Shi S; Wang E; Yu J; Ngai C
    J Med Econ; 2017 Jan; 20(1):54-62. PubMed ID: 27603498
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Accounting for Cured Patients in Cost-Effectiveness Analysis.
    Othus M; Bansal A; Koepl L; Wagner S; Ramsey S
    Value Health; 2017 Apr; 20(4):705-709. PubMed ID: 28408015
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Dacarbazine, a chemotherapeutic against metastatic melanoma and a reference drug for new treatment modalities].
    Koprowska K; Czyż M
    Postepy Hig Med Dosw (Online); 2011 Nov; 65():734-51. PubMed ID: 22173438
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategies for individualizing management of patients with metastatic melanoma: a managed care perspective.
    Goldstein DA; Zeichner SB
    Am J Manag Care; 2015 Sep; 21(10 Suppl):S234-41. PubMed ID: 26619297
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Economic burden of brain metastases among patients with metastatic melanoma in a USA managed care population.
    Vekeman F; Cloutier M; Yermakov S; Amonkar MM; Arondekar B; Duh MS
    Melanoma Res; 2014 Dec; 24(6):602-10. PubMed ID: 24926818
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current systemic therapies for melanoma.
    Palathinkal DM; Sharma TR; Koon HB; Bordeaux JS
    Dermatol Surg; 2014 Sep; 40(9):948-63. PubMed ID: 25072125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimising treatment for Australian melanoma patients can save taxpayers millions of dollars annually.
    Gedye C; Boyle FM
    Med J Aust; 2015 Feb; 202(3):130. PubMed ID: 25669468
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 10.